个性化纳米医学的诊疗一体化路径。
The Theranostic Path to Personalized Nanomedicine.
作者信息
Theek Benjamin, Rizzo Larissa Y, Ehling Josef, Kiessling Fabian, Lammers Twan
机构信息
Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH - Aachen University, Aachen, Germany.
Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH - Aachen University, Aachen, Germany ; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands ; Department of Controlled Drug Delivery, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.
出版信息
Clin Transl Imaging. 2014 Feb 1;2(1):66-76. doi: 10.1007/s40336-014-0051-5.
Advances in nanotechnology and chemical engineering have led to the development of many different drug delivery systems. These 1-100(0) nm-sized carrier materials aim to increase drug concentrations at the pathological site, while avoiding their accumulation in healthy non-target tissues, thereby improving the balance between the efficacy and the toxicity of systemic (chemo-) therapeutic interventions. An important advantage of such nanocarrier materials is the ease of incorporating both diagnostic and therapeutic entities within a single formulation, enabling them to be used for theranostic purposes. We here describe the basic principles of using nanomaterials for targeting therapeutic and diagnostic agents to pathological sites, and we discuss how nanotheranostics and image-guided drug delivery can be used to personalize nanomedicine treatments.
纳米技术和化学工程的进步推动了许多不同药物递送系统的发展。这些尺寸为1至100（0）纳米的载体材料旨在提高病理部位的药物浓度，同时避免其在健康的非靶组织中蓄积，从而改善全身（化学）治疗干预的疗效与毒性之间的平衡。此类纳米载体材料的一个重要优势是易于在单一制剂中同时纳入诊断和治疗实体，使其能够用于诊疗目的。我们在此描述将纳米材料用于将治疗和诊断剂靶向输送至病理部位的基本原理，并讨论纳米诊疗学和图像引导药物递送如何用于实现纳米医学治疗的个性化。
Zotero 插件